Go to the profile of Biocad

Biocad

 
  • +7 (812) 380-49-33
  • Networkers
  • Russian Federation
Go to the profile of HAOJUN LIAN
HAOJUN LIAN

BD, Innovent Biologics

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
Go to the profile of Najoua Borkadi
Najoua Borkadi

Business Development Associate Director, University of Michigan

Founded in London (United Kingdom) in 2016, MicroQuin was born out of a collaborative and inclusive approach to research. MicroQuin is a biotechnology, R&D based company currently focusing on developing therapeutics to address a range of oncological disease. MicroQuin is progressing lead compounds into clinical trials, which offer a potential cure to Breast Cancer and other diseases.
TAHO is a specialty pharma focus on identifying, and developing new products that offer better therapeutic options to patient populations that may be under served. By utilizing company’s technology platform, it offers service niches in drug delivery. TAHO’s transdermal delivery platform allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. It transform the patient care by: . Continuous delivery, safe, reliable, and pain-free application . Improved convenience, tolerability, and dosing . Flexible drug administration TAHO’s transmucosal delivery system, delivery the drug as a thin film, an evolution from tablets or capsules. It is a better patient care with: . Convenient dosing, no water needed . No risk of choking . Taste masking Let TAHO be your partner for innovative solutions and diverse your product pipeline
ImmuneOncia was established as a joint venture between Sorrento Therapeutics, USA and Yuhan Corporation, Korea, focusing on immuno-oncology and aims to bring safe, effective immunotherapies to patients worldwide.
Go to the profile of Carmen Ramirez
Carmen Ramirez

Sales Account Executive, Springer Nature

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature